NRSN Stock Summary and Trading Ideas (Neurosense Therapeutics Ltd. - | NASDAQ:NRSN)

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Neurosense Therapeutics Ltd. - trades on the NASDAQ stock market under the symbol NRSN.

As of February 6, 2026, NRSN stock price climbed to $0.94 with 149,748 million shares trading.

NRSN has a beta of 1.28, meaning it tends to be more sensitive to market movements. NRSN has a correlation of 0.05 to the broad based SPY ETF.

NRSN has a market cap of $27.91 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, NRSN traded as high as $2.60 and as low as $.40.

NRSN has underperformed the market in the last year with a price return of -20.5% while the SPY ETF gained +15.1%. NRSN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.7% and -2.0%, respectively, while the SPY returned +3.3% and +0.2%, respectively.

NRSN support price is $.81 and resistance is $.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRSN shares will trade within this expected range on the day.